{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:37:25Z","timestamp":1790537845805,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Catalyst Pharmaceuticals, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00415-022-11231-7","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T15:21:18Z","timestamp":1660144878000},"page":"5858-5867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial"],"prefix":"10.1007","volume":"269","clinical-trial-number":[{"clinical-trial-number":"nct03781479","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"2017-004600-22","registry":"10.18810\/euctr"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-6821","authenticated-orcid":false,"given":"Silvia","family":"Bonanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-9445","authenticated-orcid":false,"given":"Riccardo","family":"Giossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Zanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Porcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Iannacone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Ingenito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Iyadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zorica","family":"Stevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stojan","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-5173","authenticated-orcid":false,"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"11231_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","volume":"19","author":"G Hamilton","year":"2013","unstructured":"Hamilton G, Gillingwater TH (2013) Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 19:40\u201350. https:\/\/doi.org\/10.1016\/j.molmed.2012.11.002","journal-title":"Trends Mol Med"},{"key":"11231_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ajmg.10425","volume":"110","author":"S Ogino","year":"2002","unstructured":"Ogino S, Leonard DGB, Rennert H et al (2002) Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet 110:301\u2013307. https:\/\/doi.org\/10.1002\/ajmg.10425","journal-title":"Am J Med Genet"},{"key":"11231_CR3","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH (2008) Spinal muscular atrophy. Lancet (Lond, Engl) 371:2120\u20132133. https:\/\/doi.org\/10.1016\/S0140-6736(08)60921-6","journal-title":"Lancet (Lond, Engl)"},{"key":"11231_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","volume":"2","author":"TL Munsat","year":"1992","unstructured":"Munsat TL, Davies KE (1992) International SMA consortium meeting (26\u201328 June 1992, Bonn, Germany). Neuromuscul Disord 2:423\u2013428","journal-title":"Neuromuscul Disord"},{"key":"11231_CR5","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.2174\/15665240113139990044","volume":"13","author":"BB Goulet","year":"2013","unstructured":"Goulet BB, Kothary R, Parks RJ (2013) At the \u201cjunction\u201d of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression. Curr Mol Med 13:1160\u20131174. https:\/\/doi.org\/10.2174\/15665240113139990044","journal-title":"Curr Mol Med"},{"key":"11231_CR6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT (2015) Spinal muscular atrophy. Neurol Clin 33:831\u2013846. https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004","journal-title":"Neurol Clin"},{"key":"11231_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"key":"11231_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M et al (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385:427\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa2102047","journal-title":"N Engl J Med"},{"key":"11231_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1706198","journal-title":"N Engl J Med"},{"key":"11231_CR10","doi-asserted-by":"publisher","first-page":"e000164","DOI":"10.1136\/bmjno-2021-000164","volume":"3","author":"WD Arnold","year":"2021","unstructured":"Arnold WD, Severyn S, Zhao S et al (2021) Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen. BMJ Neurol Open 3:e000164. https:\/\/doi.org\/10.1136\/bmjno-2021-000164","journal-title":"BMJ Neurol Open"},{"key":"11231_CR11","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","volume":"2","author":"H Chaytow","year":"2021","unstructured":"Chaytow H, Faller KME, Huang Y-T, Gillingwater TH (2021) Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med 2:100346. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100346","journal-title":"Cell Rep Med"},{"key":"11231_CR12","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1212\/WNL.0b013e3182749eca","volume":"79","author":"RI Wadman","year":"2012","unstructured":"Wadman RI, Vrancken AFJE, van den Berg LH, van der Pol WL (2012) Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology 79:2050\u20132055. https:\/\/doi.org\/10.1212\/WNL.0b013e3182749eca","journal-title":"Neurology"},{"key":"11231_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.nmd.2017.07.007","volume":"27","author":"MC Pera","year":"2017","unstructured":"Pera MC, Luigetti M, Pane M et al (2017) 6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction. Neuromuscul Disord 27:879\u2013882. https:\/\/doi.org\/10.1016\/j.nmd.2017.07.007","journal-title":"Neuromuscul Disord"},{"key":"11231_CR14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","volume":"74","author":"J Montes","year":"2010","unstructured":"Montes J, McDermott MP, Martens WB et al (2010) Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74:833\u2013838. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d3e308","journal-title":"Neurology"},{"key":"11231_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/mus.24081","volume":"50","author":"J Montes","year":"2014","unstructured":"Montes J, Dunaway S, Garber CE et al (2014) Leg muscle function and fatigue during walking in spinal muscular atrophy type 3. Muscle Nerve 50:34\u201339. https:\/\/doi.org\/10.1002\/mus.24081","journal-title":"Muscle Nerve"},{"key":"11231_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/16501970510030156","volume":"37","author":"IJM de Groot","year":"2005","unstructured":"de Groot IJM, de Witte LP (2005) Physical complaints in ageing persons with spinal muscular atrophy. J Rehabil Med 37:258\u2013262. https:\/\/doi.org\/10.1080\/16501970510030156","journal-title":"J Rehabil Med"},{"key":"11231_CR17","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","volume":"255","author":"S Piepers","year":"2008","unstructured":"Piepers S, van den Berg LH, Brugman F et al (2008) A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol 255:1400\u20131404. https:\/\/doi.org\/10.1007\/s00415-008-0929-0","journal-title":"J Neurol"},{"key":"11231_CR18","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/(sici)1097-4598(199809)21:9<1196::aid-mus11>3.0.co;2-q","volume":"21","author":"P Maddison","year":"1998","unstructured":"Maddison P, Newsom-Davis J, Mills KR (1998) Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert\u2013Eaton myasthenic syndrome. Muscle Nerve 21:1196\u20131198. https:\/\/doi.org\/10.1002\/(sici)1097-4598(199809)21:9%3c1196::aid-mus11%3e3.0.co;2-q","journal-title":"Muscle Nerve"},{"key":"11231_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/jnnp.65.2.213","volume":"65","author":"P Maddison","year":"1998","unstructured":"Maddison P, Newsom-Davis J, Mills KR (1998) Distribution of electrophysiological abnormality in Lambert\u2013Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 65:213\u2013217. https:\/\/doi.org\/10.1136\/jnnp.65.2.213","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11231_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A et al (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893\u2013902. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03019.x","journal-title":"Eur J Neurol"},{"key":"11231_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/NDT.S10464","volume":"7","author":"S Lindquist","year":"2011","unstructured":"Lindquist S, Stangel M (2011) Update on treatment options for Lambert\u2013Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat 7:341\u2013349. https:\/\/doi.org\/10.2147\/NDT.S10464","journal-title":"Neuropsychiatr Dis Treat"},{"key":"11231_CR22","doi-asserted-by":"publisher","first-page":"205031211881901","DOI":"10.1177\/2050312118819013","volume":"6","author":"S Bonanno","year":"2018","unstructured":"Bonanno S, Pasanisi MB, Frangiamore R et al (2018) Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study. SAGE Open Med 6:2050312118819013. https:\/\/doi.org\/10.1177\/2050312118819013","journal-title":"SAGE Open Med"},{"key":"11231_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/mus.25230","volume":"54","author":"S Verma","year":"2016","unstructured":"Verma S, Mazell SN, Shah DA (2016) Amifampridine phosphate in congenital myasthenic syndrome. Muscle Nerve 54:809\u2013810","journal-title":"Muscle Nerve"},{"key":"11231_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ana.410270411","volume":"27","author":"CTJ Bever","year":"1990","unstructured":"Bever CTJ, Leslie J, Camenga DL et al (1990) Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol 27:421\u2013427. https:\/\/doi.org\/10.1002\/ana.410270411","journal-title":"Ann Neurol"},{"key":"11231_CR25","unstructured":"CHMP Zenas, INN-amifampridine. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/firdapse-epar-public-assessment-report_en.pdf. Accessed 1 Nov 2021"},{"key":"11231_CR26","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/mus.25070","volume":"53","author":"SJ Oh","year":"2016","unstructured":"Oh SJ, Shcherbakova N, Kostera-Pruszczyk A et al (2016) Amifampridine phosphate (Firdapse(\u00ae)) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve 53:717\u2013725. https:\/\/doi.org\/10.1002\/mus.25070","journal-title":"Muscle Nerve"},{"key":"11231_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O\u2019Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP et al (2007) An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 17:693\u2013697. https:\/\/doi.org\/10.1016\/j.nmd.2007.05.009","journal-title":"Neuromuscul Disord"},{"key":"11231_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","volume":"17","author":"MC Pera","year":"2017","unstructured":"Pera MC, Coratti G, Forcina N et al (2017) Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol 17:39. https:\/\/doi.org\/10.1186\/s12883-017-0790-9","journal-title":"BMC Neurol"},{"key":"11231_CR29","doi-asserted-by":"publisher","first-page":"l4378","DOI":"10.1136\/bmj.l4378","volume":"366","author":"K Dwan","year":"2019","unstructured":"Dwan K, Li T, Altman DG, Elbourne D (2019) CONSORT 2010 statement: extension to randomised crossover trials. BMJ 366:l4378. https:\/\/doi.org\/10.1136\/bmj.l4378","journal-title":"BMJ"},{"key":"11231_CR30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/j.1468-1331.2010.02992.x","volume":"17","author":"VA Sansone","year":"2010","unstructured":"Sansone VA, Panzeri M, Montanari M et al (2010) Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases. Eur J Neurol 17:1178\u20131187. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.02992.x","journal-title":"Eur J Neurol"},{"key":"11231_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0883073813511859","volume":"29","author":"S Orcesi","year":"2014","unstructured":"Orcesi S, Ariaudo G, Mercuri E et al (2014) A new self-report quality of life questionnaire for children with neuromuscular disorders: presentation of the instrument, rationale for its development, and some preliminary results. J Child Neurol 29:167\u2013181. https:\/\/doi.org\/10.1177\/0883073813511859","journal-title":"J Child Neurol"},{"key":"11231_CR32","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1749-6632.1993.tb22949.x","volume":"681","author":"DB Sanders","year":"1993","unstructured":"Sanders DB, Howard JFJ, Massey JM (1993) 3,4-Diaminopyridine in Lambert\u2013Eaton myasthenic syndrome and myasthenia gravis. Ann N Y Acad Sci 681:588\u2013590. https:\/\/doi.org\/10.1111\/j.1749-6632.1993.tb22949.x","journal-title":"Ann N Y Acad Sci"},{"key":"11231_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/wnl.54.3.603","volume":"54","author":"DB Sanders","year":"2000","unstructured":"Sanders DB, Massey JM, Sanders LL, Edwards LJ (2000) A randomized trial of 3,4-diaminopyridine in Lambert\u2013Eaton myasthenic syndrome. Neurology 54:603\u2013607. https:\/\/doi.org\/10.1212\/wnl.54.3.603","journal-title":"Neurology"},{"key":"11231_CR34","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA (1989) 3,4-diaminopyridine in the treatment of Lambert\u2013Eaton myasthenic syndrome. N Engl J Med 321:1567\u20131571. https:\/\/doi.org\/10.1056\/NEJM198912073212303","journal-title":"N Engl J Med"},{"key":"11231_CR35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/mus.21422","volume":"40","author":"SJ Oh","year":"2009","unstructured":"Oh SJ, Claussen GG, Hatanaka Y, Morgan MB (2009) 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 40:795\u2013800. https:\/\/doi.org\/10.1002\/mus.21422","journal-title":"Muscle Nerve"},{"key":"11231_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/clpt.2009.35","volume":"86","author":"PW Wirtz","year":"2009","unstructured":"Wirtz PW, Verschuuren JJ, van Dijk JG et al (2009) Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert\u2013Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 86:44\u201348. https:\/\/doi.org\/10.1038\/clpt.2009.35","journal-title":"Clin Pharmacol Ther"},{"key":"11231_CR37","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1111\/ene.14472","volume":"27","author":"B Stolte","year":"2020","unstructured":"Stolte B, Bois J-M, Bolz S et al (2020) Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy. Eur J Neurol 27:2586\u20132594. https:\/\/doi.org\/10.1111\/ene.14472","journal-title":"Eur J Neurol"},{"key":"11231_CR38","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","volume":"71","author":"AD Goodman","year":"2008","unstructured":"Goodman AD, Brown TR, Cohen JA et al (2008) Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 71:1134\u20131141. https:\/\/doi.org\/10.1212\/01.wnl.0000326213.89576.0e","journal-title":"Neurology"},{"key":"11231_CR39","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2020.07.007","volume":"30","author":"CA Chiriboga","year":"2020","unstructured":"Chiriboga CA, Marra J, LaMarca NM et al (2020) Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients. Neuromuscul Disord 30:693\u2013700. https:\/\/doi.org\/10.1016\/j.nmd.2020.07.007","journal-title":"Neuromuscul Disord"},{"key":"11231_CR40","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S et al (2020) Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 91:1166\u20131174. https:\/\/doi.org\/10.1136\/jnnp-2020-323822","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11231_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R et al (2020) Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 19:317\u2013325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30037-5","journal-title":"Lancet Neurol"},{"key":"11231_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10954-3","author":"S Bonanno","year":"2022","unstructured":"Bonanno S, Zanin R, Bello L et al (2022) Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen. J Neurol. https:\/\/doi.org\/10.1007\/s00415-021-10954-3","journal-title":"J Neurol"},{"key":"11231_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-180342","volume":"6","author":"S Dunaway Young","year":"2019","unstructured":"Dunaway Young S, Montes J, Kramer SS et al (2019) Perceived fatigue in spinal muscular atrophy: a pilot study. J Neuromuscul Dis 6:109\u2013117. https:\/\/doi.org\/10.3233\/JND-180342","journal-title":"J Neuromuscul Dis"},{"key":"11231_CR44","doi-asserted-by":"publisher","first-page":"e019932","DOI":"10.1136\/bmjopen-2017-019932","volume":"8","author":"M Stam","year":"2018","unstructured":"Stam M, Wadman RI, Wijngaarde CA et al (2018) Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2\u20134 (SPACE trial). BMJ Open 8:e019932. https:\/\/doi.org\/10.1136\/bmjopen-2017-019932","journal-title":"BMJ Open"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11231-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:06:19Z","timestamp":1744203979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11231-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["11231"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11231-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"13 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Bonanno received honoraria for advisory board activities and compensation for travel and congress participation from Sanofi Genzyme, Biogen and Roche; R. Giossi received support for congress participation from Mylan; R. Zanin received funds for travel and congress participation from Biogen; V. Porcelli has nothing to disclose; C. Iannacone has received honoraria for statistical consultancy from Roche, Bayer-Schering, ReiThera, Abiogen, and MolMed; G. Baranello received speaker and consulting fees from Biogen, Novartis Gene Therapies, Inc. (AveXis), and Roche and has worked as principal investigator of SMA studies sponsored by Novartis Gene Therapies, Inc., and Roche; G. Ingenito has corporate appointment with Catalyst Pharmaceuticals; S. Iyadurai has corporate appointment with Catalyst Pharmaceuticals; Z. Stevic reports following conflicts of interest, all outside this work: receiving lecture honoraria from Pfizer and Roche; S. Peric reports following conflicts of interest, all outside this work: receiving lecture honoraria from Pfizer, Teva Actavis, Berlin Chemie Menarini, Mylan, Worwag, Adoc, and Salveo, research grants from Kedrion and Octapharma, consultant fees from argenx and Mylan, and travel grants from Octapharma, Kedrion, Teva Actavis, Sanofi Genzyme, Pfizer, Roche, Adoc, and Berlin Chemie Menarini, and reports no other conflicts of interest outside or related to this work; L. Maggi has received honoraria for speaking, advisory boards and compensation for congress participations from Sanofi Genzyme, Roche and Biogen, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The trial was conducted in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidance Good Clinical Practice, the 1964 Declaration of Helsinki and its later amendments, local applicable law and regulatory requirements, was approved by institutional review boards and ethical committees of each participating center, and was registered in ClinicalTrials.gov (NCT03781479) and EUDRACT (2017-004600-22). All patients provided a written informed consent before any study procedure was performed, i.e., before the screening visit.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}